Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Starbucks Corp — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Starbucks Corp trades at $93.99 (market cap $104.88B). The key difference: Starbucks Corp is far larger — about 11.8× Kymera Therapeutics Inc. Common Stock's market cap, and Starbucks Corp pays a 2.74% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Starbucks Corp for 190 Days on average.
| KYMR | SBUX | |
|---|---|---|
Market Cap | $8.87B | $104.88B |
Volume | 779,107 | 9,749,448 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $108.55 |
52-Week Low | $55.80 | $79.60 |
Typical Hold Time | 0 Days | 190 Days |
Enterprise Value | $8.26B | $123.70B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SBUX trades at $93.25, up 1.05% on the day, amid a bearish technical signal and mixed fundamentals. Recent earnings show beats in Q1 and Q2 2026 but a miss in Q4 2025, with net income margin at 5.17%. The company is undergoing a strategic reset, closing 250 North American stores to optimize its portfolio, while facing headwinds from labor relations and geopolitical pressures in China.
The stock presents a cautious outlook with a high P/E of 53.18 suggesting premium valuation, yet analyst consensus targets $115.50 imply upside. Key risks include execution of store closures, competitive pressures, and macroeconomic sensitivity. Investor sentiment is divided, balancing restructuring potential against near-term operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
